BNTX250117C75000
- 38.56
- 0.000.00%
BioNTech Newsroom
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist Financial Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $172
BioNTech Analyst Ratings
Truist Financial Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $172
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
Express News | Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity
Private Equity Firms Who Hold 43% of BioNTech SE (NASDAQ:BNTX) Gained 6.8%, Institutions Profited as Well
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
BioNTech SE's (NASDAQ:BNTX) Shareholders Might Be Looking For Exit
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)
NIH Settlement 'Manageable Headwind' for BioNTech, Pfizer, Says Morgan Stanley
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
4 Stocks to Watch on Friday: NFLX, AAPL on $4T Watch and More
BioNTech Settles Lawsuits With US NIH, UPenn Over Covid Vaccine Royalties
BioNTech Settles Royalty Dispute With NIH for $791.5 Million